Search Results - "Giralt, S. A."

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS by Luger, S M, Ringdén, O, Zhang, M-J, Pérez, W S, Bishop, M R, Bornhauser, M, Bredeson, C N, Cairo, M S, Copelan, E A, Gale, R P, Giralt, S A, Gulbas, Z, Gupta, V, Hale, G A, Lazarus, H M, Lewis, V A, Lill, M C, McCarthy, P L, Weisdorf, D J, Pulsipher, M A

“…Although reduced-intensity conditioning (RIC) and non-myeloablative (NMA)-conditioning regimens have been used for over a decade, their relative efficacy vs…”
Get full text

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia by Pegram, H J, Purdon, T J, van Leeuwen, D G, Curran, K J, Giralt, S A, Barker, J N, Brentjens, R J

“…Disease relapse or progression is a major cause of death following umbilical cord blood (UCB) transplantation (UCBT) in patients with high-risk, relapsed or…”
Get full text

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis by Khoury, H J, Kukreja, M, Goldman, J M, Wang, T, Halter, J, Arora, M, Gupta, V, Rizzieri, D A, George, B, Keating, A, Gale, R P, Marks, D I, McCarthy, P L, Woolfrey, A, Szer, J, Giralt, S A, Maziarz, R T, Cortes, J, Horowitz, M M, Lee, S J

“…Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in…”
Get full text

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant by EAPEN, M, GIRALT, S. A, RINGDEN, O, BREDESON, C. N, MARTINO, R, GALES, R. P, CAIRO, M. S, LITZOW, M. R, DELIMA, M, HOROWITZ, M. M, KLEIN, J. P, WAGNER, J. E, ZHANG, M.-J, TALLMAN, M. S, MARKS, D. I, CAMITTA, B. M, CHAMPLIN, R. E

“…Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and…”
Get full text

Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up by Parmar, S, Kongtim, P, Champlin, R, Dinh, Y, Elgharably, Y, Wang, M, Bashir, Q, Shah, J J, Shah, N, Popat, U, Giralt, S A, Orlowski, R Z, Qazilbash, M H

“…Optimal treatment approach continues to remain a challenge for systemic light chain amyloidosis (AL). So far, Auto-SCT is the only modality associated with…”
Get full text

Symptom burden in patients undergoing autologous stem-cell transplantation by ANDERSON, K. O, GIRALT, S. A, MENDOZA, T. R, BROWN, J. O, NEUMANN, J. L, MOBLEY, G. M, WANG, X. S, CLEELAND, C. S

“…Patients who undergo autologous peripheral blood stem cell (PBSC) transplantation experience multiple symptoms that adversely affect quality of life. We…”
Get full text

Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies by ÖZDEMIR, E, SALIBA, R. M, SHPALL, E. J, QAZILBASH, M. H, MOLLDREM, J. J, CHEMALY, R. F, KOMANDURI, K. V, CHAMPLIN, R. E, COURIEL, D. R, GIRALT, S. A, DE LIMA, M, KHOURI, I. F, HOSING, C, KORNBLAU, S. M, ANDERLINI, P

“…We analyzed the clinical factors associated with late cytomegalovirus (CMV) reactivation in a group of 269 consecutive recipients of allogeneic stem cell…”
Get full text

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation by Giralt, S.A., Mangan, K.F., Maziarz, R.T., Bubalo, J.S., Beveridge, R., Hurd, D.D., Mendoza, F.L., Rubenstein, E.B., DeGroot, T.J., Schuster, M.W.

“…Explore safety and efficacy of three palonosetron-containing regimens for emesis prevention over 7 days in multiple myeloma (MM) patients receiving melphalan…”
Get full text

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR by Popat, U, de Lima, M J, Saliba, R M, Anderlini, P, Andersson, B S, Alousi, A M, Hosing, C, Nieto, Y, Parmar, S, Khouri, I F, Kebriaei, P, Qazilbash, M, Champlin, R E, Giralt, S A

“…A total of 36 consecutive patients with AML in CR underwent reduced-intensity allogeneic hematopoietic SCT (RISCT) with fludarabine and melphalan conditioning…”
Get full text

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma by Kazmi, S M A, Saliba, R M, Donato, M, Wang, M, Hosing, C, Qureshi, S, Anderlini, P, Popat, U, Champlin, R E, Giralt, S A, Qazilbash, M H

“…In spite of high-dose chemotherapy followed by autologous hematopoietic SCT multiple myeloma (MM) eventually recurs, highlighting the need for more effective…”
Get full text

Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin by GHOSH, S, CHAMPLIN, R. E, WHIMBEY, E, ENGLUND, J, GIRALT, S. A, ROLSTON, K, RAAD, I, JACOBSON, K, NEUMANN, J, IPPOLITI, C, MALLIK, S

“…Respiratory syncytial virus (RSV) is an important cause of serious respiratory illness in blood and marrow transplant (BMT) recipients. In some subsets of…”
Get full text

Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative BCR-ABL-negative chronic myelogenous leukemia by MITTAL, P, SALIBA, R. M, GIRALT, S. A, SHAHJAHAN, M, COHEN, A. I, KARANDISH, S, ONIDA, F, BERAN, M, CHAMPLIN, R. E, DE LIMA, M

“…The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a…”
Get full text

Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation by JABBOUR, E, RONDON, G, ANDERLINI, P, GIRALT, S. A, COURIEL, D. R, CHAMPLIN, R. E, KHOURI, I. F

“…Graft failure is a life-threatening complication of allogeneic stem cell transplantation (SCT). We assessed the feasibility of performing a second SCT after…”
Get full text

Outcome of alveolar hemorrhage in hematopoietic stem cell transplant recipients by GUPTA, S, JAIN, A, DICKEY, B. F, EAPEN, G. A, WARNEKE, C. L, GUPTA, A, SHANNON, V. R, MORICE, R. C, ONN, A, JIMENEZ, C. A, BASHOURA, L, GIRALT, S. A

“…Alveolar hemorrhage (AH) is a frequent, serious complication of hematopoietic stem cell transplantation (HSCT). To study the incidence of AH, its clinical…”
Get full text

Management of lymphoma recurrence after allogeneic transplantation : the relevance of graft-versus-lymphoma effect by VAN BESIEN, K. W, DE LIMA, M, PRZEPIORKA, D, GAJEWSKI, J. L, CHAMPLIN, R. E, GIRALT, S. A, MOORE, D. F, KHOURI, I. F, RONDON, G, MEHRA, R, ANDERSSON, B. S, DYER, C, CLEARY, K

“…Donor lymphocyte infusions, by virtue of a graft-versus-tumor effect, have been shown to induce remissions in leukemia that recurs after allogeneic bone marrow…”
Get full text

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer by Ueno, N T, Rondón, G, Mirza, N Q, Geisler, D K, Anderlini, P, Giralt, S A, Andersson, B S, Claxton, D F, Gajewski, J L, Khouri, I F, Körbling, M, Mehra, R C, Przepiorka, D, Rahman, Z, Samuels, B I, van Besien, K, Hortobagyi, G N, Champlin, R E

“…To evaluate the feasibility of allogeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with…”
Get more information

Comorbidity indices in hematopoietic stem cell transplantation: a new report card by ALAMO, J, SHAHJAHAN, M, LAZARUS, H. M, DE LIMA, M, GIRALT, S. A

“…Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT)…”
Get full text

Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma by QAZILBASH, M. H, SALIBA, R. M, KEBRIAEI, P, POPAT, U, ALOUS, A. M, CHAMPLIN, R. E, GIRALT, S. A, HOSING, C, MENDOZA, F, QURESHI, S. R, WEBER, D. M, WANG, M, FLOSSER, T, COURIEL, D. R, DE LIMA, M

“…Several clinical trials have shown the superiority of autologous stem cell transplantation over conventional dose therapy for patients with multiple myeloma…”
Get full text

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies by Qazilbash, M H, Wieder, E, Thall, P F, Wang, X, Rios, R, Lu, S, Kanodia, S, Ruisaard, K E, Giralt, S A, Estey, E H, Cortes, J, Komanduri, K V, Clise-Dwyer, K, Alatrash, G, Ma, Q, Champlin, R E, Molldrem, J J

“…PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes…”
Get full text

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response by ANDERLINI, P, ACHOLONU, S. A, CHAMPLIN, R. E, OKOROJI, G-J, ANDERSSON, B. S, COURIEL, D. R, DE LIMA, M. J, DONATO, M. L, KHOURI, I. F, GIRALT, S. A, UENO, N. T

“…Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs)…”
Get full text